ストックスクリーナーアプリを入手
31.38
2.12%
-0.6457
前日終値:
$32.03
開ける：
$32.24
24時間の取引高:
1.99M
Relative Volume:
0.33
時価総額：
$36.52B
収益：
$17.53B
当期純損益:
$1.58B
株価収益率:
23.32
EPS:
1.3457
ネットキャッシュフロー:
$444.18M
1週間 パフォーマンス:
-2.57%
1か月 パフォーマンス:
-0.41%
6か月 パフォーマンス:
-0.03%
1年 パフォーマンス:
+95.22%
1日の値動き範囲:
$31.13
$32.26
1週間の範囲:
$31.13
$32.69
52週間の値動き範囲:
$14.99
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
名前
Teva Pharmaceutical Industries Ltd Adr
セクター
電話
972 (3) 914-8213
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.36 | 37.30B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
17.11 | 54.77B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.09 | 44.48B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.32 | 32.10B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
531.02 | 22.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-12-05 | 開始されました | Scotiabank | Sector Outperform |
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-05-28 | 開始されました | Truist | Buy |
| 2025-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-07-10 | アップグレード | Argus | Hold → Buy |
| 2024-03-08 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-02-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | アップグレード | Jefferies | Hold → Buy |
| 2024-01-03 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-11-27 | アップグレード | UBS | Neutral → Buy |
| 2023-07-06 | アップグレード | UBS | Sell → Neutral |
| 2023-05-25 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-18 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-01-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-11-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | UBS | Neutral → Sell |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-08-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-06-14 | 再開されました | UBS | Neutral |
| 2022-05-17 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-05-04 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-03-25 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | ダウングレード | Argus | Buy → Hold |
| 2021-10-28 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | ダウングレード | UBS | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 開始されました | Oppenheimer | Perform |
| 2020-08-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 再開されました | Goldman | Neutral |
| 2020-06-01 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-24 | 再開されました | Citigroup | Neutral |
| 2020-04-06 | アップグレード | UBS | Neutral → Buy |
| 2020-02-24 | ダウングレード | Edward Jones | Hold → Sell |
| 2019-11-12 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-10-17 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-08-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 開始されました | Wolfe Research | Peer Perform |
| 2019-07-15 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 再開されました | Credit Suisse | Neutral |
| 2019-07-05 | アップグレード | Argus | Hold → Buy |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-06-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | ダウングレード | UBS | Buy → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2019-03-07 | 再開されました | UBS | Buy |
すべてを表示
Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
TEVA Stock Price | Analyst Target 42.38 & Strong Buy Consensus - eToro
Teva stock leans on its generic drug base. - ad-hoc-news.de
883035 Forecast — Price Target — Prediction for 2027 - TradingView
TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz
How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm
TEVA Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
TEV Forecast — Price Target — Prediction for 2027 - TradingView
TEVA Forecast — Price Target — Prediction for 2027 - TradingView
TEVA/N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Enterprise value to EBITDA forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR - TradingView
Teva Pharmaceutical Industries Limited Sponsored ADR - TradingView
TEVA News | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth - TradingView
How Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback - Sahm
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome - Yahoo Finance
Teva submits new drug application for pediatric Tourette treatment By Investing.com - Investing.com Canada
FOCUS-US progesterone supplies tighten as menopause treatment demand grows - Sahm
Teva Extends Neuroscience Focus With Emalex Deal And Valuation Upside Potential - Sahm
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy - Sahm
symbol__ Stock Quote Price and Forecast - CNN
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
How Investors May Respond To Teva (TEVA) Pivoting From Generics Toward Higher-Margin Branded Therapies - Sahm
Teva stock hits 52-week high at $32.02 By Investing.com - Investing.com Nigeria
Assessing Teva (NYSE:TEVA) Valuation After New IMPACT-TD Registry Findings On Tardive Dyskinesia - Sahm
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings - ChartMill
Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits
Updating Moat and Valuation for Teva to Reflect Improved Outlook - Morningstar
Teva: Upgrading Moat and Raising Valuation on Portfolio Improvements and Deep Pipeline - Morningstar
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today - Sahm
A Look At Teva (NYSE:TEVA) Valuation After EMA Accepts Filing For Monthly Schizophrenia Injection - Sahm
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LSX:883035 - TradingView
Will Teva’s New TD Data on Young Adults Shift Its Neuroscience-Focused Investment Narrative (TEVA)? - Sahm
Teva Pharmaceutical’s SWOT analysis: stock navigates growth reset - Investing.com
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ
収益
当期純利益
現金流量
EPS
0.25%
0.51%
大文字化:
|
ボリューム (24 時間):